WO1997007826A1 - In vivo electroporation of cells - Google Patents

In vivo electroporation of cells Download PDF

Info

Publication number
WO1997007826A1
WO1997007826A1 PCT/US1996/013591 US9613591W WO9707826A1 WO 1997007826 A1 WO1997007826 A1 WO 1997007826A1 US 9613591 W US9613591 W US 9613591W WO 9707826 A1 WO9707826 A1 WO 9707826A1
Authority
WO
WIPO (PCT)
Prior art keywords
cells
vivo
accordance
electroporation
treated
Prior art date
Application number
PCT/US1996/013591
Other languages
French (fr)
Other versions
WO1997007826A9 (en
Inventor
Claude Y. Nicolau
Richard Heller
Andrew Atkin
Richard Gilbert
Mark Jaroszeski
Original Assignee
Cbr Laboratories, Inc.
University Of South Florida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cbr Laboratories, Inc., University Of South Florida filed Critical Cbr Laboratories, Inc.
Priority to AU68557/96A priority Critical patent/AU6855796A/en
Publication of WO1997007826A1 publication Critical patent/WO1997007826A1/en
Publication of WO1997007826A9 publication Critical patent/WO1997007826A9/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/89Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microinjection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Definitions

  • This invention relates to electroporation of living cells in vivo for intracellular delivery of nucleic acids including genes of interest for the expression of desired protein or antisense nucleotides for the suppression or expression of certain intracellular proteins.
  • Liposomes and positively charged polymers like poly-L-Lysine have been used during the past years as in vivo delivery systems for gene therapy and cancer treatment, (Nicolau et al Proc. Natl. Acad. Sci. USA 80, 1068-1072, 1983 Duzgunes N. and Feigner P.L., 1993, Methods Enzymol., 221 :303-306).
  • these approaches have clearly demonstrated serious disadvantages including low efficiency in vivo and relatively low efficacy of intracellular DNA delivery.
  • the nature of liposome delivery to cells in organs other than liver and lung make liposomes a relatively inefficient delivery vehicle for gene therapy for various practical applications including treatment of many solid tumors.
  • Electroporation has been shown to be the most efficient method for DNA delivery in vitro (Neuman et al, 1982, EMBO J., 1 :841-845).
  • the mechanism of DNA transfer in this method is based on formation of membrane pores followed by DNA electrophoresis through these pores into the cells (Neuman E. et al., 1982, EMBO J., 1 :841-845).
  • the mechanism of electroporation does not demonstrate many ofthe disadvantages of other gene transfer approaches.
  • the procedure can be applied to any cell type without limitations.
  • Still another object of this invention is to provide treated cells in accordance with the treatment ofthe methods of this invention.
  • a method of treating living cells in vivo comprises introducing foreign nucleic acids by electroporation into cells in vivo to cause suppression or expression of at least one protein in vivo.
  • the method can be carried out as a means of introducing genes into cells in vivo.
  • the nucleic acid introduced alters protein expression to make the cells sensitive to destruction when treated with a drug nontoxic to normal cells. This method is useful as a cancer treatment for man, animals and mammals.
  • nucleic acids including DNA is passed into living cells in vivo through the cell membrane and is taken up in the cell DNA as known in the art.
  • Fig. 1 is a diagrammatic illustration showing a top plan view of electrode placement for electroporation in an exposed medial lobe of a rat liver
  • Fig. 2 is a diagrammatic cross-sectional view through the liver of Fig. 1 diagrammatically showing the needles and injected DNA;
  • Fig. 3 is a summary of luciferase activity 48 hours after electroporation using the methods of this invention with pulses at varying field strength;
  • Fig. 4 shows expression of luciferase expression after electroporation
  • Fig. 5 shows the dose response curve for luciferase expression plating the dose injected into a rat liver or control (no injection of DNA, just electroporation) against luciferase activity in AU arbitrary light units
  • Fig. 6 is a flow cytometry assay of ⁇ -galactosidase expression after in vivo electroporation without the gene injected;
  • Fig. 7 is the same as Fig. 6 with the gene injected at 25 mg/ml.
  • Each histogram of Figs. 6 and 7 plots the log of fluorescent intensity (abscissae) versus number of cells population (ordinate).
  • living cells can be treated in vivo by introducing foreign nucleic acid by electroporation into cells in vivo to cause suppression or expression of at least one protein in vivo.
  • the method can be used to treat living cells by introducing foreign nucleic acid such as genes into cells for gene therapy to alter a genetic characteristic ofthe cells as, for example, to correct genetic problems and disorders as in replacement gene therapy and in cancer treatment.
  • the nucleic acids to be injected into cells in vivo includes nucleic acids of any size, whole or partial genes, DNA, RNA and generally any nucleic acid sequence which are injected by electroporation.
  • the nucleic acids can be foreign nucleic acids or can supplement nucleic acids already present in the cells.
  • cells are meant to include living cells, organs, tissues and solid cancers. Thus, malignancies can be treated, particularly solid tumors, by the methods of this invention as will be described.
  • the cells are meant to include cells of man and animals including, but not limited to. all mammalian species.
  • In vivo treatment is treatment in or at the body while the cells are living as, for example, electroporation of organs through the skin ofthe body or after surgical procedures to expose organs.
  • electroporation can be carried out with the use of electroporation needle displays which are of extremely small size and which can be combined in cannula and endoscopic fiber optic instruments.
  • Endoscopes are preferred instruments for reaching internal solid tumors since they can carry viewing optics as well as nucleic acid injection needles and electrodes allowing in vivo steps to be carried out internally without the need for surgery. It is preferred that needle penetration for injection of nucleic acids and application of an applied voltage, preferably follow a multi-needle design as, for example, shown in Figs.
  • Fig. 2 shows a cross section thereof with DNA previously injected through hypodermic syringes/needles, which also apply the voltage.
  • a central electrode needle surrounded by eight additional needles.
  • the eight electrode needles are equispaced around a 0.5 cm radius from the center needle.
  • the conductive needles can be 0.3 millimeter diameter. This electrode is inserted so that the central needle enters the center ofthe area for the quantity of DNA to be injected as shown in Fig. 1.
  • the second electrode utilizes six needles that can be equispaced around 1 cm diameter.
  • the electrode can be inserted so that the site ofthe DNA injection is within a circular region encompassed by the needles.
  • the needles can protrude for example approximately 5 mm into the liver or other cells, organs, cancers or tissues which are to be treated. Electroporation techniques for injection into cells in vitro are well-known in the art and such known techniques can be used, see Eur. J. Cancer, Vol. 27, No. 1, pp 68-72, 1991, Mir et al., Biochemical and Biophysical Research Communications, pp 938-943, Vol. 194, No. 2, 1993, Salford et al. and Cancer, Vol. 72, No.
  • the needle arrangement ofthe electrode be arranged to give the smallest overall diameter ofthe electrode needle array.
  • plural needle arrays are incorporated in endoscopic instruments of known types.
  • the electrodes pass through the endoscopes.
  • the needles can be used to treat remote areas in the body accessed through endoscopes as, for example, treating solid tumors ofthe pancreas, brain, gastrointestinal tract. liver, skin, kidneys, gynecological tumors and cancer of other organs ofthe body.
  • Electroporation in vivo for the local intracellular delivery of nucleic acid can be achieved by the local injection of any desired nucleic acids.
  • Nucleic acids as used in this application include DNA, RNA and synthetic oligonucleotides.
  • the nucleic acids can be injected into the tissue of interest followed by either a single or multiple rectangular pulse or exponential electric pulses with strength ranging from 200 V/cm to 1 ,500 V/cm and the time constant ranging from 1 microsecond to 100 millisecond.
  • the nucleic acid is used in aqueous or other suspension, with the concentration ranging from 0.001 mg/ml to 10 mg/ml and is injected into the tissue of interest in a dose ranging from 0.001 to 10 mg/kilogram or more.
  • the electric pulses must be essentially applied locally to the tissue injected with said nucleic acid of interest within period of time ranging from 5 seconds to 30 minutes after injection using needle-like electrodes from 1 mm to 5 mm in length and separated by 0.4 mm to 20 mm distance from each other.
  • the multiple pulses with different parameters including electric field strength, time constant and shape can be applied to the tissue injected with the said nucleic acid for an efficient electroporation of cellular membrane and intracellular delivery by means of transmembrane electrophoresis.
  • the preferred electroporation device in the present invention consists of a fiberoptic endoscopic component combined with injection needles connected to a syringe for injection and needle-like electrodes connected to an electric pulse generator.
  • the injection needle and needle ⁇ like electrodes are normally within the endoscope device and can be moved in the operating position and inserted into a tissue independently under the visual control of a fiberoptic component ofthe device.
  • Genes which can be transferred to tumor or cancer cells for therapeutic purposes can be any ofthe known genes for any known therapeutic purposes. Specific useful genes include: herpes virus thymidine kinase. Wagner M.J. et al. Proc. Natl. Acad. Sci. USA, Vol.
  • Genes which can be injected in vivo for replacement therapy for genetic disorders include those encoding for ⁇ -glucocerebrosidase (Gaucher disease) and - ⁇ -25-hydroxylase (phenylketonuria).
  • Rat livers can be electroporated in vivo with a plasmid carrying the luciferase gene site or the gene encoding for ⁇ -galactosidase as a reporter.
  • the conditions described in the first example below can be used to inject the luciferase gene or the ⁇ -galactosidase into a rat liver.
  • the animals can be sacrificed at various times after electroporation and luciferase activity can be measured in a liver homogenate.
  • the data shown in Figs. 3-5 indicate that luciferase expression can be observed for at least 21 days after an electroporation procedure, according to the first example below.
  • a protocol for gene transfer into rat liver organs is established.
  • a 3 mg/kg dose of atropine is administered by subcutaneous injection into the right flank of a male rat.
  • Ten minutes later a 45 mg/kg dose of sodium pentobarbital is introduced by intraperitoneal injection.
  • the rat is then completely anesthetized and the liver is surgically exposed. This is preferably done by making a transfer incision starting from the mid-sagittal position, approximately 1 cm caudal to the xiphoid process, extending 3 to 4 cm toward the dorsal surface ofthe rat.
  • the medial lobe (both halves) ofthe liver is exposed by drawing it out ofthe incision without causing tissue damage.
  • Nucleic acid or DNA is injected into the right central lobe ofthe exposed liver tissue.
  • 100 ⁇ g of DNA in 100 ⁇ l of sterile injectable saline are used.
  • a time period of 1.5 minutes is allowed to elapse after injection in order to allow for diffusion of the DNA. Electrodes are inserted into the liver tissue.
  • the first is comprised of a central needle surrounded by eight additional needles.
  • the eight needles are equispaced around a 0.5 cm radius from the center needle. This electrode is inserted so that the central needle enters the center of the injected quantity of DNA (see Figure 1).
  • the second electrode utilizes 6 needles that are equispaced around a 1 cm diameter. This electrode is inserted so that the site of nucleic and/or DNA injection is within the circular region encompassed by the needles. All needles on both electrode types protrude 5 mm. Pulses are administered to the tissue. Pulsing is slightly different for each ofthe two electrode types.
  • the center needle functions as the anode and all eight needles positioned around the annulus ofthe electrode body function as the cathode. The distance between the center needle and any annular needle is 5 mm.
  • the 6 needle electrode uses a rotating electric field. For this type of pulsing six 99 ⁇ second rectangular DC pulses are delivered. The electric field strength is 1000 V/cm, and the duty cycle is 1 second.
  • the area that was encompassed by the electrode is marked using sutures.
  • the electrode is removed, and the liver is placed back into its natural position. The incision is closed with surgical staples.
  • the animal is euthanized by administering a 100 mg/kg dose of sodium pentobarbital by intraperitoneal injection. The treated tissue is then removed for analysis.
  • Results are obtained which demonstrate that electroporation can be efficiently used in vivo. Pulses with the field strength up to 2 kV/cm were applied to the live tissues without affecting experimental animals but the optimal field strength for electroporation appears to be significantly lower.
  • Fig. 3 summarizes the results of these experiments. Electric pulses with the field strength between 1 kV/cm and 2 kV/cm allow an efficient transfection of liver cells and a high level of luciferase expression as measured at 48 hours after electroporation. The field strength above 2 kV/cm led to necrosis ofthe electroporated tissue, possibly due to the insufficient heat dissipation. The level of expression in electroporated cells is probably higher than the one we detected experimentally because all measurements were performed in the liver tissue homogenate from a broad area covering the electroporated region. Accurate location of the electroporated area is limited by technical factors.
  • luciferase expression at various times after in vivo electroporation demonstrates that the level of luciferase activity in tissue reaches the maximal value at 48 hours followed by decrease to 5-7% ofthe initial activity during the first week and remains stable for three weeks after electroporation (Fig. 4).
  • Fig. 4 The efficiency ofthe reporter gene expression after in vivo electroporation strongly depends on the amount of plasmid DNA and optimal results were detected using 25 ⁇ g of DNA while an increase in this amount leads to the reduction of luciferase activity (Fig. 5).
  • liver tissue was transfected with the ⁇ Gal gene as described above in the first example.
  • Hepatocytes were isolated from the dissected liver tissue using Collagenase treatment.
  • the isolated cells were treated with chloroquine to block lysosome activity followed by incubation with the lipophilic ⁇ Gal substrate C ]2 FDG (Molecular Probes Eugene Oregon).
  • the activity ofthe reporter gene was assayed using fiowcytometry.
  • Fig. 6 shows results of this experiment.
  • the treatment of melanoma is achieved by an injection of 0.1-0.5 ml of plasmid DNA carrying the herpesvirus gene of thymidine kinase under the control ofthe CMV promoter with a concentration in normal saline of about 1 mg/ml followed by DNA diffusion in the tumor tissue for about 2 min.
  • ganciclovir is administered to a patient at therapeutical doses of 5 mg per kilogram weight ofthe patient intravenously every twelve hours for 14 days.
  • the nontoxic ganciclovir drug is converted into a toxic compound by thymidine kinase expressed in the electroporated tumor cells with cytotoxic effect on these treated cells and neighboring cells.
  • the treatment of pancreatic tumors of either acinar or endocrine phenotype is achieved by providing endoscopic electroporation.
  • An endoscopic device comprising a fiber optic component, injection needle and electroporation needle-like electrodes is passed through the esophagus and the front end ofthe instrument is moved to the tumor site under the control ofthe fiber optic component of said device.
  • the injection needle is moved forward from the device and inserted into the tissue under visual control using a fiber optic component ofthe device.
  • An injection of 0.1-0.5 ml of plasmid DNA carrying the he ⁇ esvirus gene of thymidine kinase under the control ofthe CMV promoter with concentration of about 1 mg/ml is injected into the tumor.
  • Injected DNA is allowed to diffuse in the tumor tissue for 5 min.
  • Six circularly arranged needle-like electrodes mounted within the device are moved at working position from said device and inserted into the tumor tissue containing the plasmid DNA.
  • Eight rectangular electric pulses of 99 ⁇ sec with electric field strength of 1000 V/cm (applied tension of 9 volts) are delivered to the tumor tissue with 1 second interval through each pair of opposite electrodes. The procedure is repeated at four spaced tumor sites.
  • Ganciclovir is administered to a patient at therapeutical doses, as in the second example, for the intracellular conversion ofthe nontoxic drug into the toxic compound by thymidine kinase expressed in the electroporated tumor cells with cytoxic effect on these cells, and the cells surrounding them.
  • the treatment of inherited beta-glucocerebrosidase deficiency is achieved by electroporation of normal liver tissue with plasmid DNA carrying the gene of beta-glucocerebrosidase under the control of CMV promoter as described in Example 3.
  • the treatment of tumors of gastrointestinal origin including tumors ofthe stomach, pancreatic tumors of ductal phenotype and tumors of duodenum is achieved through the noninvasive oral access to the tumor site using an endoscopic device as described above and electroporation procedure described in Example 3.
  • RNA such as genes which cause living cells to express protein materials which are sensitive to specific drugs are preferred for use in treating tumors in accordance with this invention.
  • a gene encoding the herpes virus thymidine kinase can be injected into cells at a dosage rate of 10 mg/kilogram and preferably around 0.125 mg/kilogram, as set forth above, using the electroporation parameter set forth above to have the cells produce the protein thymidine kinase.
  • the treated cells which were treated by electroporation in vivo undergo a reaction between the ganciclovir and thymidine kinase to form a toxic substance which kills the transformed cells and cells surrounding them.
  • ganciclovir which can be used can be Cytovene, a ganciclovir sodium sterile powder produced by Syntex Laboratories of Palo Alto, California. Dosages of about 1.25 to about 5mg per kilogram of body weight administered intravenously at a constant rate over one hour, every 12 hours, for fourteen to twenty-one days, can be used to treat tumors so as to kill some or all of such tumors.

Abstract

A method of treating living mammalians in vivo is carried out by introducing foreign nucleic acid by electroporation into cells in vivo to cause suppression or expression of at least one protein in vivo. The method can be carried out to alter genetic characteristics of cells in vivo.

Description

IN VIVO ELECTROPORATION OF CELLS
Related Application
This application claims the benefit of U.S. Provisional Application No. 60/002,911, filed August 29, 1995.
Field of the Invention
This invention relates to electroporation of living cells in vivo for intracellular delivery of nucleic acids including genes of interest for the expression of desired protein or antisense nucleotides for the suppression or expression of certain intracellular proteins.
Background of the Invention
Liposomes and positively charged polymers like poly-L-Lysine have been used during the past years as in vivo delivery systems for gene therapy and cancer treatment, (Nicolau et al Proc. Natl. Acad. Sci. USA 80, 1068-1072, 1983 Duzgunes N. and Feigner P.L., 1993, Methods Enzymol., 221 :303-306). However, these approaches have clearly demonstrated serious disadvantages including low efficiency in vivo and relatively low efficacy of intracellular DNA delivery. The nature of liposome delivery to cells in organs other than liver and lung make liposomes a relatively inefficient delivery vehicle for gene therapy for various practical applications including treatment of many solid tumors.
Electroporation has been shown to be the most efficient method for DNA delivery in vitro (Neuman et al, 1982, EMBO J., 1 :841-845). The mechanism of DNA transfer in this method is based on formation of membrane pores followed by DNA electrophoresis through these pores into the cells (Neuman E. et al., 1982, EMBO J., 1 :841-845). The mechanism of electroporation does not demonstrate many ofthe disadvantages of other gene transfer approaches. Moreover, the procedure can be applied to any cell type without limitations.
Summary of the Invention
It is an object of this invention to provide a method for treating living cells as in normal as well as cancer cells of organs or solid tumors of all kinds, in vivo, by introducing foreign nucleic acid in vivo by electroporation to cause suppression or expression of at least one protein in vivo. It is a still further object of this invention to provide a method of treating living cells in vivo by introducing foreign nucleic acids using electroporation, into cells in vivo to act as gene therapy for a multitude of disorders.
Still another object of this invention is to provide treated cells in accordance with the treatment ofthe methods of this invention.
According to the invention, a method of treating living cells in vivo comprises introducing foreign nucleic acids by electroporation into cells in vivo to cause suppression or expression of at least one protein in vivo. The method can be carried out as a means of introducing genes into cells in vivo. In a preferred embodiment, the nucleic acid introduced alters protein expression to make the cells sensitive to destruction when treated with a drug nontoxic to normal cells. This method is useful as a cancer treatment for man, animals and mammals.
It is a feature of this invention that known electroporation techniques can be used in vivo to alter living cells and thus affect and treat humans and animals. In many cases, unwanted tumors and genetic defects and diseases can be prevented and/or cured, or at least partially cured. The nucleic acids including DNA is passed into living cells in vivo through the cell membrane and is taken up in the cell DNA as known in the art.
Brief Description of the Drawings The above and other objects, advantages and features ofthe present invention will be better understood from a reading ofthe following specification in conjunction with the accompanying drawings, in which:
Fig. 1 is a diagrammatic illustration showing a top plan view of electrode placement for electroporation in an exposed medial lobe of a rat liver; Fig. 2 is a diagrammatic cross-sectional view through the liver of Fig. 1 diagrammatically showing the needles and injected DNA;
Fig. 3 is a summary of luciferase activity 48 hours after electroporation using the methods of this invention with pulses at varying field strength;
Fig. 4 shows expression of luciferase expression after electroporation; Fig. 5 shows the dose response curve for luciferase expression plating the dose injected into a rat liver or control (no injection of DNA, just electroporation) against luciferase activity in AU arbitrary light units; Fig. 6 is a flow cytometry assay of β-galactosidase expression after in vivo electroporation without the gene injected; and
Fig. 7 is the same as Fig. 6 with the gene injected at 25 mg/ml. Each histogram of Figs. 6 and 7 plots the log of fluorescent intensity (abscissae) versus number of cells population (ordinate).
Detailed Description of the Preferred Embodiment
Generally, living cells can be treated in vivo by introducing foreign nucleic acid by electroporation into cells in vivo to cause suppression or expression of at least one protein in vivo. The method can be used to treat living cells by introducing foreign nucleic acid such as genes into cells for gene therapy to alter a genetic characteristic ofthe cells as, for example, to correct genetic problems and disorders as in replacement gene therapy and in cancer treatment.
The nucleic acids to be injected into cells in vivo, as the term is used herein, includes nucleic acids of any size, whole or partial genes, DNA, RNA and generally any nucleic acid sequence which are injected by electroporation. The nucleic acids can be foreign nucleic acids or can supplement nucleic acids already present in the cells.
As used herein, "cells" are meant to include living cells, organs, tissues and solid cancers. Thus, malignancies can be treated, particularly solid tumors, by the methods of this invention as will be described. The cells are meant to include cells of man and animals including, but not limited to. all mammalian species.
In vivo treatment is treatment in or at the body while the cells are living as, for example, electroporation of organs through the skin ofthe body or after surgical procedures to expose organs. In some cases, electroporation can be carried out with the use of electroporation needle displays which are of extremely small size and which can be combined in cannula and endoscopic fiber optic instruments. Endoscopes are preferred instruments for reaching internal solid tumors since they can carry viewing optics as well as nucleic acid injection needles and electrodes allowing in vivo steps to be carried out internally without the need for surgery. It is preferred that needle penetration for injection of nucleic acids and application of an applied voltage, preferably follow a multi-needle design as, for example, shown in Figs. 1 and 2 where the needles are shown to penetrate a site in the exposed medial lobe of a rat liver, Fig. 2 shows a cross section thereof with DNA previously injected through hypodermic syringes/needles, which also apply the voltage. Preferably two different electrode designs are used. In the first, there is a central electrode needle surrounded by eight additional needles. The eight electrode needles are equispaced around a 0.5 cm radius from the center needle. The conductive needles can be 0.3 millimeter diameter. This electrode is inserted so that the central needle enters the center ofthe area for the quantity of DNA to be injected as shown in Fig. 1. The second electrode utilizes six needles that can be equispaced around 1 cm diameter. The electrode can be inserted so that the site ofthe DNA injection is within a circular region encompassed by the needles. In all cases, the needles can protrude for example approximately 5 mm into the liver or other cells, organs, cancers or tissues which are to be treated. Electroporation techniques for injection into cells in vitro are well-known in the art and such known techniques can be used, see Eur. J. Cancer, Vol. 27, No. 1, pp 68-72, 1991, Mir et al., Biochemical and Biophysical Research Communications, pp 938-943, Vol. 194, No. 2, 1993, Salford et al. and Cancer, Vol. 72, No. 12, 1993, pp 3694-3700, Beuhradeh et al., all of which articles are incorporated herein by reference. It is preferred that the needle arrangement ofthe electrode be arranged to give the smallest overall diameter ofthe electrode needle array. Preferably, plural needle arrays are incorporated in endoscopic instruments of known types. The electrodes pass through the endoscopes. Thus, the needles can be used to treat remote areas in the body accessed through endoscopes as, for example, treating solid tumors ofthe pancreas, brain, gastrointestinal tract. liver, skin, kidneys, gynecological tumors and cancer of other organs ofthe body.
Electroporation in vivo for the local intracellular delivery of nucleic acid can be achieved by the local injection of any desired nucleic acids. Nucleic acids as used in this application include DNA, RNA and synthetic oligonucleotides. The nucleic acids can be injected into the tissue of interest followed by either a single or multiple rectangular pulse or exponential electric pulses with strength ranging from 200 V/cm to 1 ,500 V/cm and the time constant ranging from 1 microsecond to 100 millisecond. The nucleic acid is used in aqueous or other suspension, with the concentration ranging from 0.001 mg/ml to 10 mg/ml and is injected into the tissue of interest in a dose ranging from 0.001 to 10 mg/kilogram or more. The electric pulses must be essentially applied locally to the tissue injected with said nucleic acid of interest within period of time ranging from 5 seconds to 30 minutes after injection using needle-like electrodes from 1 mm to 5 mm in length and separated by 0.4 mm to 20 mm distance from each other. The multiple pulses with different parameters including electric field strength, time constant and shape can be applied to the tissue injected with the said nucleic acid for an efficient electroporation of cellular membrane and intracellular delivery by means of transmembrane electrophoresis.
The preferred electroporation device in the present invention consists of a fiberoptic endoscopic component combined with injection needles connected to a syringe for injection and needle-like electrodes connected to an electric pulse generator. The injection needle and needle¬ like electrodes are normally within the endoscope device and can be moved in the operating position and inserted into a tissue independently under the visual control of a fiberoptic component ofthe device. Genes which can be transferred to tumor or cancer cells for therapeutic purposes can be any ofthe known genes for any known therapeutic purposes. Specific useful genes include: herpes virus thymidine kinase. Wagner M.J. et al. Proc. Natl. Acad. Sci. USA, Vol. 78, pp 1441-1445, 1981, interleukin-2 (IL-2), Taniguchi T et al., Nature, Vo. 302, pp 305-310, 1983 and Devos R., et al., Nucleic Acid Research, Vol. II, pp 4307-4323, 1983,
HLA-B4403, Fleischhauer K et al., Tissue Antigens Vol. 37, pp 133-137, 1991,
Gene for Encoding Receptor for Low Density Liposuction, Wilson, J.M. et al., J. Biol. Chem., Vol. 267, pp 963-967, 1992.
Genes which can be injected in vivo for replacement therapy for genetic disorders include those encoding for β-glucocerebrosidase (Gaucher disease) and -α-25-hydroxylase (phenylketonuria).
The application of the described in vivo electroporation method can be demonstrated using a rat model. Rat livers can be electroporated in vivo with a plasmid carrying the luciferase gene site or the gene encoding for β-galactosidase as a reporter. The conditions described in the first example below can be used to inject the luciferase gene or the β-galactosidase into a rat liver. The animals can be sacrificed at various times after electroporation and luciferase activity can be measured in a liver homogenate. The data shown in Figs. 3-5 indicate that luciferase expression can be observed for at least 21 days after an electroporation procedure, according to the first example below. In a first specific example of this invention a protocol for gene transfer into rat liver organs is established. A 3 mg/kg dose of atropine is administered by subcutaneous injection into the right flank of a male rat. Ten minutes later a 45 mg/kg dose of sodium pentobarbital is introduced by intraperitoneal injection.
The rat is then completely anesthetized and the liver is surgically exposed. This is preferably done by making a transfer incision starting from the mid-sagittal position, approximately 1 cm caudal to the xiphoid process, extending 3 to 4 cm toward the dorsal surface ofthe rat. The medial lobe (both halves) ofthe liver is exposed by drawing it out ofthe incision without causing tissue damage. Nucleic acid or DNA is injected into the right central lobe ofthe exposed liver tissue. Typically 100 μg of DNA in 100 μl of sterile injectable saline are used. A time period of 1.5 minutes is allowed to elapse after injection in order to allow for diffusion of the DNA. Electrodes are inserted into the liver tissue.
Two different electrode designs are used. The first is comprised of a central needle surrounded by eight additional needles. The eight needles are equispaced around a 0.5 cm radius from the center needle. This electrode is inserted so that the central needle enters the center of the injected quantity of DNA (see Figure 1). The second electrode utilizes 6 needles that are equispaced around a 1 cm diameter. This electrode is inserted so that the site of nucleic and/or DNA injection is within the circular region encompassed by the needles. All needles on both electrode types protrude 5 mm. Pulses are administered to the tissue. Pulsing is slightly different for each ofthe two electrode types. For the 9 needle electrode, eight 99 μsecond rectangular DC pulses with an electric field strength of 1000 V/cm and a duty cycle of 1 second are delivered. The center needle functions as the anode and all eight needles positioned around the annulus ofthe electrode body function as the cathode. The distance between the center needle and any annular needle is 5 mm. The 6 needle electrode uses a rotating electric field. For this type of pulsing six 99 μsecond rectangular DC pulses are delivered. The electric field strength is 1000 V/cm, and the duty cycle is 1 second. The area that was encompassed by the electrode is marked using sutures. The electrode is removed, and the liver is placed back into its natural position. The incision is closed with surgical staples. At the desired time after treatment, the animal is euthanized by administering a 100 mg/kg dose of sodium pentobarbital by intraperitoneal injection. The treated tissue is then removed for analysis.
Results are obtained which demonstrate that electroporation can be efficiently used in vivo. Pulses with the field strength up to 2 kV/cm were applied to the live tissues without affecting experimental animals but the optimal field strength for electroporation appears to be significantly lower. Fig. 3 summarizes the results of these experiments. Electric pulses with the field strength between 1 kV/cm and 2 kV/cm allow an efficient transfection of liver cells and a high level of luciferase expression as measured at 48 hours after electroporation. The field strength above 2 kV/cm led to necrosis ofthe electroporated tissue, possibly due to the insufficient heat dissipation. The level of expression in electroporated cells is probably higher than the one we detected experimentally because all measurements were performed in the liver tissue homogenate from a broad area covering the electroporated region. Accurate location of the electroporated area is limited by technical factors.
Detection of luciferase expression at various times after in vivo electroporation demonstrates that the level of luciferase activity in tissue reaches the maximal value at 48 hours followed by decrease to 5-7% ofthe initial activity during the first week and remains stable for three weeks after electroporation (Fig. 4). These results may indicate that the long term- expression of reporter gene might be supported by stable transfectants because the transient expression achieved with other transfection methods decreases gradually during 2-3 weeks after transfection. The efficiency ofthe reporter gene expression after in vivo electroporation strongly depends on the amount of plasmid DNA and optimal results were detected using 25 μg of DNA while an increase in this amount leads to the reduction of luciferase activity (Fig. 5). These results differ from data regarding electroporation in vitro where DNA dose-response curve clearly reaches the saturation at concentrations above 100 μg/ml. There is not presently an explanation of this difference.
One ofthe important advantages of electroporation in vitro is a high efficiency of intracellular DNA delivery. To assay the efficiency ofthe in vivo procedure, the liver tissue was transfected with the βGal gene as described above in the first example. Hepatocytes were isolated from the dissected liver tissue using Collagenase treatment. The isolated cells were treated with chloroquine to block lysosome activity followed by incubation with the lipophilic βGal substrate C]2FDG (Molecular Probes Eugene Oregon). The activity ofthe reporter gene was assayed using fiowcytometry. Fig. 6 shows results of this experiment. Cells isolated from mock-electroporated liver tissue showed no βGal activity, whereas the cell suspension prepared from βGal-transfected liver contains about 30% of βGal-positive cells. The real number of efficiently transfected cells in the electroporated area might be significantly higher due to the uncertainties in the accurate location ofthe transfected tissue. In a further example, the treatment of melanoma is achieved by an injection of 0.1-0.5 ml of plasmid DNA carrying the herpesvirus gene of thymidine kinase under the control ofthe CMV promoter with a concentration in normal saline of about 1 mg/ml followed by DNA diffusion in the tumor tissue for about 2 min. The needle-like electrodes mounted according to Fig. 1 are inserted into an in vivo melanoma tumor and surrounding skin tissues of a male human patient. Eight rectangular electric pulses of 99 μsec with electric field strength of 1000 V/cm are delivered to the tumor tissue with 1 second intervals for 15 min. Ganciclovir is administered to a patient at therapeutical doses of 5 mg per kilogram weight ofthe patient intravenously every twelve hours for 14 days. The nontoxic ganciclovir drug is converted into a toxic compound by thymidine kinase expressed in the electroporated tumor cells with cytotoxic effect on these treated cells and neighboring cells.
In another embodiment ofthe present invention, the treatment of pancreatic tumors of either acinar or endocrine phenotype is achieved by providing endoscopic electroporation. An endoscopic device comprising a fiber optic component, injection needle and electroporation needle-like electrodes is passed through the esophagus and the front end ofthe instrument is moved to the tumor site under the control ofthe fiber optic component of said device. The injection needle is moved forward from the device and inserted into the tissue under visual control using a fiber optic component ofthe device. An injection of 0.1-0.5 ml of plasmid DNA carrying the heφesvirus gene of thymidine kinase under the control ofthe CMV promoter with concentration of about 1 mg/ml is injected into the tumor. Injected DNA is allowed to diffuse in the tumor tissue for 5 min. Six circularly arranged needle-like electrodes mounted within the device are moved at working position from said device and inserted into the tumor tissue containing the plasmid DNA. Eight rectangular electric pulses of 99 μsec with electric field strength of 1000 V/cm (applied tension of 9 volts) are delivered to the tumor tissue with 1 second interval through each pair of opposite electrodes. The procedure is repeated at four spaced tumor sites. Ganciclovir is administered to a patient at therapeutical doses, as in the second example, for the intracellular conversion ofthe nontoxic drug into the toxic compound by thymidine kinase expressed in the electroporated tumor cells with cytoxic effect on these cells, and the cells surrounding them. According to the present invention, the treatment of inherited beta-glucocerebrosidase deficiency (Gaucher's disease) is achieved by electroporation of normal liver tissue with plasmid DNA carrying the gene of beta-glucocerebrosidase under the control of CMV promoter as described in Example 3.
In another embodiment ofthe present invention, the treatment of tumors of gastrointestinal origin including tumors ofthe stomach, pancreatic tumors of ductal phenotype and tumors of duodenum is achieved through the noninvasive oral access to the tumor site using an endoscopic device as described above and electroporation procedure described in Example 3.
It should be noted that either DNA or RNA such as genes which cause living cells to express protein materials which are sensitive to specific drugs are preferred for use in treating tumors in accordance with this invention. Thus, a gene encoding the herpes virus thymidine kinase can be injected into cells at a dosage rate of 10 mg/kilogram and preferably around 0.125 mg/kilogram, as set forth above, using the electroporation parameter set forth above to have the cells produce the protein thymidine kinase. When treated with ordinary dosages of ganciclovir, the treated cells which were treated by electroporation in vivo undergo a reaction between the ganciclovir and thymidine kinase to form a toxic substance which kills the transformed cells and cells surrounding them.
In this case, ganciclovir which can be used can be Cytovene, a ganciclovir sodium sterile powder produced by Syntex Laboratories of Palo Alto, California. Dosages of about 1.25 to about 5mg per kilogram of body weight administered intravenously at a constant rate over one hour, every 12 hours, for fourteen to twenty-one days, can be used to treat tumors so as to kill some or all of such tumors.

Claims

1. A method of treating living mammalian cells in vivo comprising selecting living cells in vivo to be treated, introducing foreign nucleic acid by electroporation into cells in vivo to cause suppression or expression of at least one protein in vivo.
2. A method in accordance with the method of claim 1 wherein said cells are cancer cells.
3. A method in accordance with the method of claim 2 wherein said nucleic acid is a gene.
4. A method in accordance with claim 3 wherein said gene encodes for a protein which, when expressed, makes said cells sensitive to destruction when treated in vivo with a drug nontoxic to normal body cells.
5. A method in accordance with the method of claim 4 wherein said gene is a gene encoding heφes virus thymidine kinase and said drug is ganciclovir.
6. A method in accordance with the method of claim 5 wherein said drug is intravenously administered.
7. A method in accordance with claim 1 wherein said foreign nucleic acid is selected from the class consisting of genes, antisense oligonucleotides, DNA, RNA.
8. A method in accordance with the method of claim 1 wherein said living cells are selected from the group consisting of organs, solid tumors, and tissues.
9. A method in accordance with the method of claim 8, wherein said living cells are pancreatic tumor cells. - l l - lO. A method in accordance with claim 2 and further comprising said cells comprising a solid tumor, and said electroporation being carried out on said tumor internally.
11. A method in accordance with claim 10 and further comprising the step of introducing electroporation electrodes to said tumor by the use of an internal cannula.
12. A method in accordance with claim 1 1 wherein said cannula is an endoscope carrying viewing optics.
13. A treated living cell in vivo treated by the method of claim 2.
14. A treated living cell in vivo treated by the method of claim 4.
15. A method of treating living mammalian cells in vivo, comprising: selecting living cells to be treated in vivo, introducing genetic material into said selected cells in vivo by electroporation to alter a genetic characteristic of said cells.
PCT/US1996/013591 1995-08-29 1996-08-26 In vivo electroporation of cells WO1997007826A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU68557/96A AU6855796A (en) 1995-08-29 1996-08-26 In vivo electroporation of cells

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US291195P 1995-08-29 1995-08-29
US60/002,911 1995-08-29

Publications (2)

Publication Number Publication Date
WO1997007826A1 true WO1997007826A1 (en) 1997-03-06
WO1997007826A9 WO1997007826A9 (en) 1997-09-18

Family

ID=21703159

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1996/013591 WO1997007826A1 (en) 1995-08-29 1996-08-26 In vivo electroporation of cells

Country Status (2)

Country Link
AU (1) AU6855796A (en)
WO (1) WO1997007826A1 (en)

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2765242A1 (en) * 1997-06-30 1998-12-31 Roussy Inst Gustave Combination of nucleic acid and electric field
FR2765241A1 (en) * 1997-06-30 1998-12-31 Roussy Inst Gustave Combination of nucleic acid and electric field
WO1999001158A1 (en) * 1997-06-30 1999-01-14 Rhone-Poulenc Rorer S.A. Improved method for transferring nucleic acid into the striped muscle and combination therefor
WO1999001157A1 (en) * 1997-06-30 1999-01-14 Rhone-Poulenc Rorer S.A. Improved method for transferring nucleic acid into multicelled eukaryotic organism cells and combination therefor
WO1999001175A1 (en) * 1997-06-30 1999-01-14 Rhone-Poulenc Rorer S.A. Device for optimized electrotransfer of nucleic acid vectors to tissues in vivo
US6181964B1 (en) 1997-08-01 2001-01-30 Genetronics, Inc. Minimally invasive apparatus and method to electroporate drugs and genes into tissue
US6216034B1 (en) 1997-08-01 2001-04-10 Genetronics, Inc. Method of programming an array of needle electrodes for electroporation therapy of tissue
US6241701B1 (en) 1997-08-01 2001-06-05 Genetronics, Inc. Apparatus for electroporation mediated delivery of drugs and genes
WO2001068889A2 (en) * 2000-03-16 2001-09-20 Malone Robert W Method for gene transfection and vaccination through skin using electropermeabilization
US6302874B1 (en) 1998-07-13 2001-10-16 Genetronics, Inc. Method and apparatus for electrically assisted topical delivery of agents for cosmetic applications
EP1194574A1 (en) * 1999-06-25 2002-04-10 Genetronics, Inc. High efficiency transfection based on low electric field strength, long pulse length
WO2003038112A2 (en) 2001-10-26 2003-05-08 Baylor College Of Medicine A composition and method to alter lean body mass and bone properties in a subject
US6654636B1 (en) 1998-07-13 2003-11-25 Genetronics, Inc. Skin and muscle-targeted gene therapy by pulsed electrical field
US6678556B1 (en) 1998-07-13 2004-01-13 Genetronics, Inc. Electrical field therapy with reduced histopathological change in muscle
US6800484B2 (en) 1998-06-24 2004-10-05 Genetronics, Inc. High efficiency transfection based on low electric field strength, long pulse length
US7361642B2 (en) 2003-08-04 2008-04-22 Vgx Pharmaceuticals, Inc. Canine specific growth hormone releasing hormone
US7517863B2 (en) 2004-01-20 2009-04-14 Vgx Pharmaceuticals, Inc. Enhanced secretion/retention of growth hormone releasing hormone (GHRH) from muscle cells by species-specific signal peptide
WO2010137021A2 (en) 2009-05-27 2010-12-02 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Method of generating connective tissue
US7922709B2 (en) 1998-07-13 2011-04-12 Genetronics, Inc. Enhanced delivery of naked DNA to skin by non-invasive in vivo electroporation
US7931640B2 (en) 1997-04-03 2011-04-26 Inovio As Method for muscle delivery of drugs, nucleic acids and other compounds
US8058253B2 (en) 2006-07-06 2011-11-15 Vgx Pharmaceuticals, Inc. Growth hormone releasing hormone treatment to decrease cholesterol levels
US8188056B2 (en) 2003-12-31 2012-05-29 Vgx Pharmaceuticals, Inc. Reducing arthritis and lameness in subjects by growth hormone releasing hormone (GHRH) supplementation

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ARCH. SURG., November 1993, Vol. 128, LYERLY et al., "Gene Delivery Systems in Surgery", pages 1197-1206. *
CANCER RESEARCH, 01 March 1996, Vol. 56, NISHI et al., "High-Efficiency In Vivo Gene Transfer Using Intraarterial Plasmid DNA Injection Following In Vivo Electroporation", pages 1050-1055. *
GENE THERAPEUTICS: METHODS AND APPLICATIONS OF DIRECT GENE TRANSFER, 1994, SUKHAREV et al., "Electrically-Induced DNA Transfer Into Cells. Electrotransfection In Vivo", pages 210-232. *
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, February 1996, Vol. 27, No. 2, GIORDANOY et al., "In Vivo Gene Delivery to the Rabbit Carotid by Electroporation", page 289A, Abstract No. 780-4. *

Cited By (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7931640B2 (en) 1997-04-03 2011-04-26 Inovio As Method for muscle delivery of drugs, nucleic acids and other compounds
CZ299473B6 (en) * 1997-06-30 2008-08-06 Rhone-Poulenc Rorer S. A. Nucleic acid and electric field as associated product for transfer of nucleic acid into cells of adversely stripped musculature
CZ299638B6 (en) * 1997-06-30 2008-10-01 Rhone-Poulenc Rorer S. A. Medicament for gene therapy that is transferred into tumors by application of weak electric field and combination product for gene therapy
WO1999001157A1 (en) * 1997-06-30 1999-01-14 Rhone-Poulenc Rorer S.A. Improved method for transferring nucleic acid into multicelled eukaryotic organism cells and combination therefor
WO1999001175A1 (en) * 1997-06-30 1999-01-14 Rhone-Poulenc Rorer S.A. Device for optimized electrotransfer of nucleic acid vectors to tissues in vivo
FR2765241A1 (en) * 1997-06-30 1998-12-31 Roussy Inst Gustave Combination of nucleic acid and electric field
US6939862B2 (en) 1997-06-30 2005-09-06 Aventis Pharma S.A. Method for transferring nucleic acid into striated muscles
WO1999001158A1 (en) * 1997-06-30 1999-01-14 Rhone-Poulenc Rorer S.A. Improved method for transferring nucleic acid into the striped muscle and combination therefor
US6528315B2 (en) 1997-06-30 2003-03-04 Aventis Pharma S.A. Method for transferring nucleic acid into multicelled eukaryotic organism cells and combination therefor
FR2765242A1 (en) * 1997-06-30 1998-12-31 Roussy Inst Gustave Combination of nucleic acid and electric field
US6233482B1 (en) 1997-08-01 2001-05-15 Genetronics, Inc. Method of electroporation mediated delivery of drugs and genes
US7412284B2 (en) 1997-08-01 2008-08-12 Genetronics, Inc. Apparatus for electroporation mediated delivery for drugs and genes
US6181964B1 (en) 1997-08-01 2001-01-30 Genetronics, Inc. Minimally invasive apparatus and method to electroporate drugs and genes into tissue
US6516223B2 (en) 1997-08-01 2003-02-04 Genetronics, Inc. Apparatus for electroporation mediated delivery for drugs and genes
US6241701B1 (en) 1997-08-01 2001-06-05 Genetronics, Inc. Apparatus for electroporation mediated delivery of drugs and genes
US6216034B1 (en) 1997-08-01 2001-04-10 Genetronics, Inc. Method of programming an array of needle electrodes for electroporation therapy of tissue
US6800484B2 (en) 1998-06-24 2004-10-05 Genetronics, Inc. High efficiency transfection based on low electric field strength, long pulse length
US6678556B1 (en) 1998-07-13 2004-01-13 Genetronics, Inc. Electrical field therapy with reduced histopathological change in muscle
US7570992B2 (en) 1998-07-13 2009-08-04 Genetronics, Inc. Electrical field therapy with reduced histopathological change in muscle
US6697669B2 (en) 1998-07-13 2004-02-24 Genetronics, Inc. Skin and muscle-targeted gene therapy by pulsed electrical field
US7922709B2 (en) 1998-07-13 2011-04-12 Genetronics, Inc. Enhanced delivery of naked DNA to skin by non-invasive in vivo electroporation
US6654636B1 (en) 1998-07-13 2003-11-25 Genetronics, Inc. Skin and muscle-targeted gene therapy by pulsed electrical field
US6947791B2 (en) 1998-07-13 2005-09-20 Genetronics, Inc. Method and apparatus for electrically assisted topical delivery of agents for cosmetic applications
US6302874B1 (en) 1998-07-13 2001-10-16 Genetronics, Inc. Method and apparatus for electrically assisted topical delivery of agents for cosmetic applications
EP1829973A3 (en) * 1999-06-25 2008-01-09 Genetronics, Inc. High efficienty transfection based on low electric field strength, low pulse length
EP1194574A1 (en) * 1999-06-25 2002-04-10 Genetronics, Inc. High efficiency transfection based on low electric field strength, long pulse length
EP1829973A2 (en) * 1999-06-25 2007-09-05 Genetronics, Inc. High efficienty transfection based on low electric field strength, low pulse length
EP1194574A4 (en) * 1999-06-25 2003-04-02 Genetronics Inc High efficiency transfection based on low electric field strength, long pulse length
WO2001068889A3 (en) * 2000-03-16 2002-04-25 Robert W Malone Method for gene transfection and vaccination through skin using electropermeabilization
WO2001068889A2 (en) * 2000-03-16 2001-09-20 Malone Robert W Method for gene transfection and vaccination through skin using electropermeabilization
WO2003038112A2 (en) 2001-10-26 2003-05-08 Baylor College Of Medicine A composition and method to alter lean body mass and bone properties in a subject
US7361642B2 (en) 2003-08-04 2008-04-22 Vgx Pharmaceuticals, Inc. Canine specific growth hormone releasing hormone
US8188056B2 (en) 2003-12-31 2012-05-29 Vgx Pharmaceuticals, Inc. Reducing arthritis and lameness in subjects by growth hormone releasing hormone (GHRH) supplementation
US7517863B2 (en) 2004-01-20 2009-04-14 Vgx Pharmaceuticals, Inc. Enhanced secretion/retention of growth hormone releasing hormone (GHRH) from muscle cells by species-specific signal peptide
US8058253B2 (en) 2006-07-06 2011-11-15 Vgx Pharmaceuticals, Inc. Growth hormone releasing hormone treatment to decrease cholesterol levels
WO2010137021A2 (en) 2009-05-27 2010-12-02 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Method of generating connective tissue

Also Published As

Publication number Publication date
AU6855796A (en) 1997-03-19

Similar Documents

Publication Publication Date Title
WO1997007826A1 (en) In vivo electroporation of cells
WO1997007826A9 (en) In vivo electroporation of cells
US20230001190A1 (en) Device and method for single-needle in vivo electroporation
US10252004B2 (en) Method and apparatus for delivery of therapeutic agents
CA2268026C (en) Method and apparatus for using electroporation mediated delivery of drugs and genes
CA2337652C (en) Skin and muscle-targeted gene therapy by pulsed electrical field
US20050277868A1 (en) Electroporation Device and Method for Delivery to Ocular Tissue
US7412284B2 (en) Apparatus for electroporation mediated delivery for drugs and genes
US20080045880A1 (en) Device and method for single-needle in vivo electroporation
CA2686855C (en) Device and method for single-needle in vivo electroporation
CN112076193B (en) Application of mequindox in preparation of medicine for treating and/or preventing diseases taking T-type calcium channel as treatment target
Balatskiy et al. Thermogenetics for cardiac pacing

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
COP Corrected version of pamphlet

Free format text: PAGES 1/5-5/5,DRAWINGS,REPLACED BY NEW PAGES 1/6-6/6;DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: CA

122 Ep: pct application non-entry in european phase